Home Companies Arbor Biotechnologies COMPANY
Clinical Phase 2
6 open jobs · last seen Oct 23, 2026 · 2 sources
Keywords: primary hyperoxaluria liver disease neurology amyotrophic lateral sclerosis Primary Hyperoxaluria Type 1 (PH1) ABO-101 Show all 6 keywords
Location: Cambridge, MA · source · Oct 14, 2026
Profile checked Oct 10, 2026
Hiring Title Location (from posting) Employer posted First seen Senior Research Associate, Histology Cambridge, MA Not stated Oct 14, 2026 Senior Research Associate, In Vivo Pharmacology Cambridge, MA Not stated Oct 14, 2026 Associate Director, Bioanalytical Sciences & Biomarkers Cambridge, MA Not stated Oct 11, 2026 Director, Analytical Development Cambridge, MA Not stated Oct 11, 2026 Director, Regulatory Affairs Cambridge, MA Not stated Oct 11, 2026
See all 6 jobs
At a glance HQ Cambridge, MA source Stage Clinical Phase 2 Latest trial 1: Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine) (Jun 16, 2025) source Raises and deals from press releases Raise Series C · $73.9M · announced Mar 18, 2025 Company release ↗ Source quote Mar 18, 2025 · Company release ↗ “Arbor Biotechnologies Announces $73.9 Million Series C Financing to Advance Novel Gene Editing Therapeutics” Raises announced in these releases: $73.9M disclosed.
From the company’s own releases; this list is partial. All raises and deals
Timeline Jun 16, 2025 Trial start 1: Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine) source ↗ Mar 18, 2025 Raise Private equity round — Series C: $73.9M (total, as published), announced Mar 18, 2025. Source: company release on GlobeNewswire. source ↗ Mar 18, 2025 Raise Series C · $73.9M source ↗ Upcoming milestones 2029-03 (ESTIMATED) · 1 · Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine) · NCT06839235 Estimated primary completion per ClinicalTrials.gov. Dates move.
Funding Raised: $73.9M. Last 2 years.
Mar 18, 2025 Private equity round — Series C: $73.9M (total, as published), announced Mar 18, 2025. Source: company release on GlobeNewswire. source ↗ Clinical trials (lead sponsor) 1 Record Title Phase Status Start Primary completion NCT06839235 Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine) 1 Recruiting Jun 16, 2025 2029-03 (estimated)
Raises and investors new Form D raises come from the company’s own SEC filing (last 2 years).
Investor Listed in the portfolio of ARCH Venture Partners (captured Oct 12, 2026). portfolio page ↗ Open jobs 6 Title Location (from posting, not HQ) Employer posted First seen Level Senior Research Associate, Histology Cambridge, MA Not stated Oct 14, 2026 Senior Description Senior Research Associate, In Vivo Pharmacology Cambridge, MA Not stated Oct 14, 2026 Senior Description Associate Director, Bioanalytical Sciences & Biomarkers Cambridge, MA Not stated Oct 11, 2026 Senior Description Director, Analytical Development Cambridge, MA Not stated Oct 11, 2026 Senior Description Director, Regulatory Affairs Cambridge, MA Not stated Oct 11, 2026 Senior Description Senior Clinical Trial Manager Remote (United States) Not stated Oct 11, 2026 Senior Description
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
Connect See your connections at Arbor Biotechnologies on LinkedIn (search by name, results not checked) LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.
LinkedIn page linked from the company's own site: source · seen 2026-10-18
